Effects of the antidepressant escitalopram in healthy volunteers Mental and Behavioural Disorders
Conditions
Interventions
The researchers administer a single oral dose of 20 mg escitalopram, a selective serotonin reuptake inhibitor (SSRI), or placebo to healthy participants in a double-blind, placebo-controlled, crossove
Sponsors
Max Planck Institute for Human Cognitive and Brain Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. 20-30 years of age 2. Naive to antidepressants
Exclusion criteria
Exclusion criteria: 1. Current or past psychiatric diagnosis as assessed with SKID-I and SKID-II interview 2. Major head trauma or neurological disease, current or in history 3. Use of psychotropic medication or of recreational drugs 4. MRI contraindications such as metal implants, claustrophobia, pregnancy 5. Smoking 6. Irregular sleep/wake rhythm (e.g., regular nightshifts or cross timeline travel)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Structural, functional, and resting-state MRI data measured during baseline, placebo, and drug sessions | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Reward and punishment processing measured using a monetary reward task, which participants perform during the functional MRI scans at baseline, placebo, and drug sessions 2. Cognitive performance measured using a cognitive load task, which participants perform during the functional MRI scans at baseline, placebo, and drug sessions | — |
Countries
Germany
Contacts
Public ContactCarolin Lewis
Outcome results
None listed